Nonhematologic malignancies after allogeneic hematopoietic stem cell transplantation: Incidence and molecular monitoring

Bone Marrow Transplantation

Volumn 34, Issue 11, 2004, Pages 981-985

  Au, W Y ^a   Chan, E C ^a   Pang, A ^a   Lie, A K W ^a   Liang, R ^a   Yuen, A P W ^a   Shek, T W H ^a   Kwong, Y L ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Chinese; Plasma DNA; Secondary malignancies; Stem cell transplantation

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DNA; MELPHALAN; METHOTREXATE; PROTEIN P15;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD ANALYSIS; CANCER INCIDENCE; CHIMERA; CHINESE; CONTROLLED STUDY; DONOR; ESOPHAGUS TUMOR; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MOLECULAR BIOLOGY; MONITORING; MOUTH TUMOR; PATHOGENESIS; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN METHYLATION; QUANTITATIVE ANALYSIS; RECIPIENT; SECOND CANCER; SQUAMOUS CELL CARCINOMA;

ADULT; CARCINOMA; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P15; DNA METHYLATION; DNA, NEOPLASM; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; NEOPLASMS, SECOND PRIMARY; RETROSPECTIVE STUDIES; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TUMOR SUPPRESSOR PROTEINS;

EID: 10044247061     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704674     Document Type: Article

References (20)

1. Lowsky R, Lipton J, Fyles G et al. Secondary malignancies after bone marrow transplantation in adults. J Clin Oncol 1994; 12: 2187-2192.
2. Socie G, Stone JV, Wingard JR et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med 1999; 341: 14-21.
3. Au WY, Lie AK, Kwong YL et al. Post-transplantation lymphoproliferative disease in Chinese: the Queen Mary Hospital experience in Hong Kong. Leuk Lymphoma 2002; 43: 1403-1407.
4. Au WY, Lie AK, Liang R et al. Aggressive hepatocellular carcinoma complicating pregnancy after autologous bone marrow transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant 2002; 29: 177-179.
5. Cancer Incidence and mortality in Hong Kong. Hong Kong Cancer Registry 2000, 5-88.
6. Au WY, Chan EC, Siu LL et al. Leukaemic relapse of donor origin after allogeneic bone marrow transplantation from a donor who later developed bronchogenic carcinoma. Br J Haematol 2002; 119: 777-780.
7. Au WY, Hawkins BR, Cheng N et al. Risk of haematological malignancies in HLA-B27 carriers. Br J Haematol 2001; 115: 320-322.
8. Szeto CH, Shek TW, Lie AK et al. Squamous cell carcinoma of the tongue complicating chronic oral mucosal graft versus host disease after allogeneic hematopoietic stem cell transplantation. Am J Hematol 2004 (in press).
9. Curtis RE, Rowlings PA, Deeg HJ et al. Solid cancers after bone marrow transplantation. N Engl J Med 1997; 336: 897-904.
10. Bhatia S, Louie AD, Bhatia R et al. Solid cancers after bone marrow transplantation. J Clin Oncol 2001; 19: 464-471.
11. Kolb HJ, Socie G, Duell T et al. Malignant neoplasms in long-term survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group. Ann Intern Med 1999; 131: 738-744.
12. Favre-Schmuziger G, Hofer S, Passweg J et al. Treatment of solid tumors following allogeneic bone marrow transplantation. Bone Marrow Transplant 2000; 25: 895-898.
13. Baker KS, DeFor TE, Burns LJ et al. New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol 2003; 21: 1352-1358.
14. Socie G, Curtis RE, Deeg HJ et al. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol 2000; 18: 348-357.
15. Deeg HJ, Witherspoon RP. Risk factors for the development of secondary malignancies after marrow transplantation. Hematol Oncol Clin North Am 1993; 7: 417-429.
16. Fetscher S, Finke J, Engelhardt R et al. Early-onset secondary malignancies after high-dose chemotherapy and autologous hematopoietic stem cell transplantation. Ann Hematol 1997; 74 73-77.
17. Thijssen MA, Swinkels DW, Ruers TJ, de Kok JB. Difference between free circulating plasma and serum DNA in patients with colorectal liver metastases. Anticancer Res 2002; 22: 421-425.
18. Sozzi G, Conte D, Leon M et al. Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 2003; 21: 3902-3908.
19. Taback B, O'Day SJ, Boasberg PD et al. Circulating DNA micro satellites: molecular determinants of response to biochemotherapy in patients with metastatic melanoma. J Natl Cancer Inst 2004; 96: 152-156.
20. Bearzatto A, Conte D, Frattini M et al. p16(INK4A) Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer. Clin Cancer Res 2002; 8 3782-3787.